28161910|t|Associations of gender and a proxy of female menopausal status with histological features of drug-induced liver injury
28161910|a|Gender and menopause may contribute to type and severity of drug-induced liver injury (DILI) by influencing host responses to injury. The aim of this study was to assess the associations of gender and female age 50 [a proxy of menopause] with histological features of liver injury in 212 adults enrolled in the Drug-Induced Liver Injury Network (DILIN) registry. All participants had a causality score of at least ' probable ', a liver biopsy within 30 days of DILI onset, and no prior chronic liver disease. Biochemical and histological injury types were classified as hepatocellular or cholestatic/mixed injury. The cohort was divided into three gender / age categories: men (41.0%), women <50 years (27.4%) and women ≥50 years of age (31.6%). Interaction of gender and age category (≥50 or not) was assessed. Hepatocellular injury was more prevalent in women <50 years vs. others (P=.002). After adjusting for biochemical injury types, black race and possible ageing effects, more severe interface hepatitis was noted in biopsies of women <50 years compared to those of men and women ≥50 years (P=.009 and P=.055 respectively). Compared to those of men, biopsies of women showed greater plasma cell infiltration, hepatocyte apoptosis, hepatocyte rosettes and lobular disarray but less iron - positive hepatocytes and histological cholestasis (P<.05). These associations persisted after excluding cases of amoxicillin/clavulanic acid, anabolic steroids or nitrofurantoin DILI which showed gender -specific distributions. Gender and a proxy of menopause were associated with various features of inflammation and injury in DILI.
28161910	0	12	Associations	T080	C0439849
28161910	16	22	gender	T032	C0079399
28161910	29	34	proxy	T096	C0600420
28161910	38	44	female	T032	C0086287
28161910	45	62	menopausal status	T201	C1513126
28161910	68	80	histological	T169	C0205462
28161910	81	89	features	T080	C2348519
28161910	93	118	drug-induced liver injury	T047	C0860207
28161910	119	125	Gender	T032	C0079399
28161910	130	139	menopause	T039	C0025320
28161910	158	162	type	T080	C0332307
28161910	167	175	severity	T080	C0439793
28161910	179	204	drug-induced liver injury	T047	C0860207
28161910	206	210	DILI	T047	C0860207
28161910	215	226	influencing	T077	C4054723
28161910	227	231	host	T001	C1167395
28161910	232	241	responses	T033	C1704632
28161910	245	251	injury	T037	C3263723
28161910	257	260	aim	T078	C1947946
28161910	269	274	study	T062	C2603343
28161910	282	288	assess	T052	C1516048
28161910	293	305	associations	T080	C0439849
28161910	309	315	gender	T032	C0079399
28161910	320	326	female	T032	C0086287
28161910	327	330	age	T032	C0001779
28161910	337	342	proxy	T096	C0600420
28161910	346	355	menopause	T039	C0025320
28161910	362	374	histological	T169	C0205462
28161910	375	383	features	T080	C2348519
28161910	387	399	liver injury	T037	C0160390
28161910	407	413	adults	T100	C0001675
28161910	430	455	Drug-Induced Liver Injury	T047	C0860207
28161910	456	463	Network	T169	C1882071
28161910	465	470	DILIN	T169	C1882071
28161910	472	480	registry	T170	C0034975
28161910	486	498	participants	T098	C0679646
28161910	505	514	causality	T169	C0015127
28161910	515	520	score	T081	C0449820
28161910	535	543	probable	T033	C0332148
28161910	549	561	liver biopsy	T060	C0193388
28161910	580	584	DILI	T047	C0860207
28161910	605	626	chronic liver disease	T047	C0341439
28161910	628	639	Biochemical	T169	C0205474
28161910	644	656	histological	T169	C0205462
28161910	657	663	injury	T037	C3263723
28161910	664	669	types	T080	C0332307
28161910	689	703	hepatocellular	T046	C0151763
28161910	707	731	cholestatic/mixed injury	T047	C1737228
28161910	737	743	cohort	T098	C0599755
28161910	748	755	divided	T169	C0332849
28161910	767	773	gender	T032	C0079399
28161910	776	779	age	T032	C0001779
28161910	780	790	categories	T170	C0683312
28161910	792	795	men	T098	C0025266
28161910	805	810	women	T098	C0043210
28161910	833	838	women	T098	C0043210
28161910	852	855	age	T032	C0001779
28161910	865	876	Interaction	T169	C1704675
28161910	880	886	gender	T032	C0079399
28161910	891	894	age	T032	C0001779
28161910	895	903	category	T170	C0683312
28161910	921	929	assessed	T052	C1516048
28161910	931	952	Hepatocellular injury	T046	C0151763
28161910	975	980	women	T098	C0043210
28161910	1032	1043	biochemical	T169	C0205474
28161910	1044	1050	injury	T037	C3263723
28161910	1051	1056	types	T080	C0332307
28161910	1058	1068	black race	T098	C0005680
28161910	1073	1081	possible	T033	C0332149
28161910	1082	1088	ageing	T040	C0001811
28161910	1089	1096	effects	T080	C1280500
28161910	1103	1109	severe	T080	C0205082
28161910	1120	1129	hepatitis	T047	C0019158
28161910	1143	1151	biopsies	T060	C0005558
28161910	1155	1160	women	T098	C0043210
28161910	1171	1179	compared	T052	C1707455
28161910	1192	1195	men	T098	C0025266
28161910	1200	1205	women	T098	C0043210
28161910	1250	1258	Compared	T052	C1707455
28161910	1271	1274	men	T098	C0025266
28161910	1276	1284	biopsies	T060	C0005558
28161910	1288	1293	women	T098	C0043210
28161910	1301	1308	greater	T081	C1704243
28161910	1309	1333	plasma cell infiltration	T047	C0391861
28161910	1335	1355	hepatocyte apoptosis	T043	C3269241
28161910	1357	1367	hepatocyte	T025	C0227525
28161910	1368	1376	rosettes	T033	C0035863
28161910	1381	1388	lobular	T080	C0205417
28161910	1407	1411	iron	T121,T123,T196	C0302583
28161910	1414	1422	positive	T033	C1514241
28161910	1423	1434	hepatocytes	T025	C0227525
28161910	1439	1451	histological	T169	C0205462
28161910	1452	1463	cholestasis	T047	C0008370
28161910	1479	1491	associations	T080	C0439849
28161910	1518	1523	cases	T169	C0868928
28161910	1527	1554	amoxicillin/clavulanic acid	T121	C0054066
28161910	1556	1573	anabolic steroids	T109,T121	C0002744
28161910	1577	1591	nitrofurantoin	T109,T121	C0028156
28161910	1592	1596	DILI	T047	C0860207
28161910	1610	1616	gender	T032	C0079399
28161910	1627	1640	distributions	T169	C1704711
28161910	1642	1648	Gender	T032	C0079399
28161910	1655	1660	proxy	T096	C0600420
28161910	1664	1673	menopause	T039	C0025320
28161910	1679	1694	associated with	T080	C0332281
28161910	1703	1711	features	T080	C2348519
28161910	1715	1727	inflammation	T046	C0021368
28161910	1732	1738	injury	T037	C3263723
28161910	1742	1746	DILI	T047	C0860207